Replimune shares plummet as skin cancer therapy fails mid-stage study
Tuesday, 5 December 2023 Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly remove cancerous lesions in a mid-stage study. However, the company stated that the rate of complete disappearance of tumors was just short of statistical significance. The study focused on improvements in complete response rate (CRR) and overall response rate (ORR). Replimune will continue the trial as planned under its agreement with Regeneron.
Wasabi Is Linked With , a ‘Really Substantial’ Memory Boost, Study Says.
A study conducted by Japan's Tohoku
University suggests that short- and long-term
memory may be improved by eating wasabi.
Wasabi was already known to have
"antibiotic, anti-cancer and anti-inflammatory
properties,"...
Tuesday, 5 December 2023
